白塞综合征心脏受累:临床驱动的心脏评估发现
该回顾性研究纳入312例白塞综合征(BS)患者,其中90例接受临床驱动的心脏评估,49例确诊心脏受累。心律失常最常见(n=15),其次为心包炎(n=12)和缺血性心脏病(n=8)。心脏受累多发生于BS诊断后中位6.1年,且多数患者处于疾病活动期并接受免疫抑制治疗,但心血管一级预防治疗不足。
要点
- 白塞综合征心脏受累在主动评估时比传统报道更常见。
- 心脏受累多发生于疾病活动期且常伴高心血管风险因素负荷。
- 多数患者首次心脏事件前未接受充分心血管一级预防治疗。
核心结论
- 白塞综合征心脏受累在主动心脏评估时比传统报道更常见。
- 心脏受累常发生于疾病活动期且心血管风险因素负荷高但预防治疗不足的患者。
- 研究结果支持白塞综合征需要心脏-风湿病整合管理。
研究设计与样本
- 回顾性研究纳入意大利佛罗伦萨三级转诊中心312例成人白塞综合征患者。
- 其中90例接受临床驱动的心脏评估,49例确诊心脏受累。
- 比较有无心脏受累患者的临床、人口学和治疗特征。
主要发现
- 心脏受累49例,心律失常最常见(n=15),其次为心包炎(n=12)和缺血性心脏病(n=8)。
- 心脏受累发生于BS诊断后中位6.1(2.5-8.7)年,部分患者先于或与诊断同时发生。
- 心脏受累时93.9%患者有活动性系统性疾病,84%正在接受免疫抑制治疗。
- 超过80%患者至少有一个传统心血管风险因素,但<40%在首次事件前接受心血管一级预防治疗。
- 男性更常发生缺血性表现,女性心律失常更常见;未观察到心脏相关死亡。
关键数值与推荐
- 心脏受累确认49例,心律失常15例,心包炎12例,缺血性心脏病8例。
- 心脏受累发生于BS诊断后中位6.1(2.5-8.7)年。
- 心脏受累时93.9%患者有活动性系统性疾病,84%接受免疫抑制治疗。
- 超过80%患者至少有一个传统心血管风险因素,<40%接受心血管一级预防治疗。
临床怎么用
- 对白塞综合征患者应主动进行心脏评估以发现心脏受累。
- 心脏受累常发生于疾病活动期,需关注疾病活动性并优化免疫抑制治疗。
- 应评估和管理传统心血管风险因素,并考虑心血管一级预防治疗。
- 建议心脏科与风湿免疫科整合管理白塞综合征患者。
局限性
- 回顾性研究设计。
- 单中心三级转诊中心队列,可能存在选择偏倚。
- 仅90例患者接受心脏评估,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize prevalence, patterns, and clinical correlates of cardiac involvement in a cohort of patients with Behçet's syndrome (BS) undergoing clinically driven cardiological assessment. METHODS: This retrospective study included adult patients with BS, followed at a tertiary referral centre (Florence, Italy), who underwent clinically driven cardiological evaluation. Clinical, demographic and therapeutic characteristics were compared in patients with and without evidence of cardiac involvement. Timing, type of cardiac involvement, disease activity, cardiovascular risk factors and treatments were analysed. RESULTS: Among 312 patients with BS, 90 underwent cardiological assessment and 49 had confirmed cardiac involvement. Arrhythmias were the most frequent manifestation (n = 15), followed by pericarditis (n = 12) and ischaemic heart disease (n = 8). Cardiac involvement occurred a median of 6.1 (2.5-8.7) years after BS diagnosis, although in a proportion of patients it preceded or coincided with diagnosis. Most patients had active systemic disease at the time of the cardiac involvement (93.9%) and were receiving immunosuppressant treatment (84%). Over 80% had at least one traditional cardiovascular risk factor, yet <40% were receiving cardiovascular primary prevention therapy before the first event. Male patients more frequently experienced ischaemic manifestations, while arrhythmias were more common in females. No cardiac-related deaths were observed. CONCLUSION: Cardiac involvement in BS is more common than traditionally reported when actively investigated. Cardiac involvement frequently occurs during active disease and in patients with a high burden of cardiovascular risk factors but suboptimal preventive therapy. These findings support the need for integrated cardio-rheumatologic management in BS.
引用
- Bettiol A, Bello F, Mazzotta R, et al. Cardiac involvement in Behçet's syndrome: findings from a clinically driven cardiological evaluation. Rheumatology (Oxford). 2026. PMID: 42391615. doi:10.1093/rheumatology/keag292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。